Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 14, 2025 08:30 ET | Source: Gradalis, Inc.

Gradalis Announces Development of Clinically Relevant Exome Sequencing Bioinformatics Pipeline to Determine Clonal Tumor Mutation Burden

Optimal therapeutic targeting of cancer involves clonal signals which are expressed within all cancer cellsGradalis applies a novel clinically relevant approach to determine clonal tumor mutation...
February 05, 2025 07:00 ET | Source: Gradalis, Inc.

Gradalis Secures FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Vigil® (Gemogenovatucel-T): An Investigational Personalized Immunotherapy for Advanced Ovarian Cancer

Recognizing clinical evidence from the Phase 2b VITAL Study of Vigil in homologous recombination proficient (HRP) patients with high clonal tumor mutation burden (cTMB-H) RMAT designation provides...
January 04, 2024 17:25 ET | Source: Gradalis, Inc.

Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers

GRAD1405 uses Gradalis’ breakthrough gene silencing bi-shRNAi technology to specifically reduce the expression of certain mutated KRAS genesExisting therapies have experienced rapid drug resistance...
December 05, 2023 08:00 ET | Source: Gradalis, Inc.

Gradalis Highlights Importance of Targeting Clonal Neoantigens in Achieving Durable Benefit in Cancer Treatment

Emerging research shows that targeting initial mutations expressed on a tumor cell surface, called clonal mutations, is critical in achieving a durable clinical benefitFor example, lung cancer...
November 16, 2023 15:12 ET | Source: Gradalis, Inc.

Gradalis Awarded $9.9 Million Grant From the Cancer Prevention and Research Institute of Texas

DALLAS, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a leader in the development of personalized anti-cancer cellular therapies for patients with solid tumors, announced today that it has been...
October 18, 2023 08:00 ET | Source: Gradalis, Inc.

Gradalis to Host Virtual KOL Discussion on the Vigil® Platform Entering Phase 2 for Platinum-Sensitive Recurrent Ovarian Cancer on October 25, 2023

DALLAS, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc. announced that it will host a virtual KOL discussion on the Vigil® platform entering Phase 2 for platinum-sensitive recurrent ovarian cancer...
September 28, 2023 08:00 ET | Source: Gradalis, Inc.

Gradalis Highlights Importance of Clonal Neoantigen Targeting for Clinical Benefit of Vigil® in Oncology Reviews Publication

Evidence from multiple researchers supports Vigil enhancement of clonal neoantigen effector cell response and correlation to relapse free survival and overall survival benefit Targeting clonal...
September 21, 2023 08:30 ET | Source: Gradalis, Inc.

Gradalis to Participate in the Cantor Global Healthcare Conference

DALLAS, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a privately held, clinical stage biotechnology company developing a personalized immunotherapy called Vigil® for patients with ovarian and...
June 06, 2023 16:05 ET | Source: Gradalis, Inc.

Gradalis Announces Peer-Reviewed Publication Demonstrating Potential of Novel 3D Scaffold Tissue Technology to Expand Vigil Platform

Technology leverages new coating process to create 3D scaffold matrix that is designed to mimic the tumor microenvironment and enable large scale tumor cell expansionDemonstrated successful increase...
March 29, 2023 16:05 ET | Source: Gradalis, Inc.

Gradalis to Participate in the Cantor Fitzgerald Future of Oncology Symposium

DALLAS, March 29, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a privately held, late-stage clinical biotechnology company developing a personalized immunotherapy called Vigil® for patients with ovarian...